Involvement of CYPIA2 in mexiletine metabolism

被引:66
作者
Nakajima, M
Kobayashi, K
Shimada, N
Tokudome, S
Yamamoto, T
Kuroiwa, Y
机构
[1] Showa Univ, Sch Pharmaceut Sci, Dept Clin Pharm, Shinagawa Ku, Tokyo 142, Japan
[2] Daiichi Pure Chem Co Ltd, Techno Res Ctr, Ibaraki, Osaka, Japan
[3] Tokyo Med Examiners Off, Tokyo, Japan
关键词
cytochrome P450; CYP2D6; bufuralol; ethoxyresorufin; furafylline; cDNA-expressed microsomes; relative activity factor;
D O I
10.1046/j.1365-2125.1998.00048.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Mexiletine has been reported to be hydroxylated by cytochrome P450 2D6 (CYP2D6) in humans. However, the involvement of CYP1A2 in the metabolism of mexiletine has been proposed based on the interaction with theophylline which is mainly metabolized by CYP1A2. The aim of this study was to clarify the role of human CYP1A2 in mexiletine metabolism. Methods Human CYP isoforms involved in mexiletine metabolism were investigated using microsomes from human liver and B-lymphoblastoid cells expressing human CYPs. The contributions of CYP1A2 and CYP2D6 to mexiletine metabolism were estimated by the relative activity factor (RAF). Results Mexiletine p- and 2-hydroxylase activities in human liver microsomes were inhibited by ethoxyresorufin and furafylline as well as quinidine. Mexiletine p- and 2-hydroxylase activities in microsomes from nine human livers correlated significantly with bufuralol 1'-hydroxylase activity (r=0.907, P<0.001 and r=0.886, P<0.01, respectively). Microsomes of B-lymphoblastoid cells expressing human CYP1A2 exhibited lower mexiletine p- and 2-hydroxylase activities than those expressing human CYP2D6. It was estimated by RAF that the major isoform involved in mexiletine metabolism was CYP2D6, and the contribution of CYP1A2 to both mexiletine p- and 2-hydroxylase activities was 7-30% in human liver microsomes. However, the K-m values of the expressed CYP1A2 (similar to 15 mu M) were almost identical with those of the expressed CYP2D6 (similar to 22 mu M) and human liver microsomes. Conclusions Mexiletine is a substrate of CYP1A2. The data obtained in this study suggest that the interaction of mexiletine with theophylline might be due to competitive inhibition of CYP1A2.
引用
收藏
页码:55 / 62
页数:8
相关论文
共 35 条
[1]  
BECKETT AH, 1977, POSTGRAD MED J, V53, P60
[2]  
BROLY F, 1990, DRUG METAB DISPOS, V18, P362
[3]   EFFECT OF QUINIDINE ON THE DEXTROMETHORPHAN O-DEMETHYLASE ACTIVITY OF MICROSOMAL FRACTIONS FROM HUMAN-LIVER [J].
BROLY, F ;
LIBERSA, C ;
LHERMITTE, M ;
BECHTEL, P ;
DUPUIS, B .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (01) :29-36
[4]   THE METABOLISM OF MEXILETINE IN RELATION TO THE DEBRISOQUINE SPARTEINE-TYPE POLYMORPHISM OF DRUG OXIDATION [J].
BROLY, F ;
VANDAMME, N ;
LIBERSA, C ;
LHERMITTE, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (04) :459-466
[5]  
CAMPBELL NPS, 1978, BRIT J CLIN PHARMACO, V6, P103, DOI 10.1111/j.1365-2125.1978.tb00833.x
[6]   CHARACTERIZATION OF THE INHIBITION OF P4501A2 BY FURAFYLLINE [J].
CLARKE, SE ;
AYRTON, AD ;
CHENERY, RJ .
XENOBIOTICA, 1994, 24 (06) :517-526
[7]  
Crespi CL., 1995, Advances in drug research, V26, P179, DOI DOI 10.1016/S0065-2490(05)80006-1
[8]  
EUGSTER HP, 1993, DRUG METAB DISPOS, V21, P43
[9]   CLINICAL PHARMACOKINETICS OF THE NEWER ANTIARRHYTHMIC AGENTS [J].
GILLIS, AM ;
KATES, RE .
CLINICAL PHARMACOKINETICS, 1984, 9 (05) :375-403
[10]  
GRECHBELANGER O, 1985, CLIN PHARMACOL THER, V37, P68